Volume : 11, Issue : 04, April – 2024
Title:
A REVIEW ARTICLE ON ETODOLAC:ANTI-INFLAMMATORY
Authors :
*R. JonaMethusala, K. Bhargavi
Abstract :
A robust, accurate and sensitive automated procedure for the determination of etodolac, an anti- inflammatory drug, in pharmaceutical formulas by sequential injection analysis, is reported. The same system was also applied to evaluate the antioxidant activity of the drug expressed as Trolox equivalent antioxidant capacity (TEAC). The methodology is based on measuring at 734 nm the decay of absorbance of a solution with the radical 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+) after its reduction by etodolac. Optimum ABTS•+ -etodolac reaction was achieved with 0.329 mL of sample and 0.205 mL of ABTS•+ solution. Etodolac was determined at concentrations up to 4.5 × 10−5 mol L−1.A solution detection limit of 6.6 × 10−6 mol L−1 was obtained under the optimised experimental conditions. A relative standard deviation (n = 10) lower than 4.7% with a sample throughput of more than 21 samples/h was obtained. No interference from excipients was observed. The developed methodology was applied in the analysis of pharmaceutical preparations and the obtained results were in good agreement with those furnished by the reference procedure with relative deviations lower than 1.4%.
Cite This Article:
Please cite this article in press K. Bhargavi et al., A review article on etodolac: Anti-inflammatory., Indo Am. J. P. Sci, 2024; 11 (04).
Number of Downloads : 10
References:
1. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science. Recommen.for the use of new methods to assess the efficacy of disease-modifying drugs in thetreatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12:263–268.
2. Adams SS, Cobb R. Non-steroidal anti-inflammatory drugs. In: Progress in Medicinal Chemistry, 5, GP Ellis, GB West, eds. London: Butterworth, 1967, 59–133.
3. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:10–14.
4. Ambrosini MV, Mariucci G, Rambotti MG, Tantucci M, Covarelli C, De Angelis L, Del Soldato P. Ultrastructural investigations on protective effects of NCX 4016 (nitro aspirin) on macrovascular endothelium in diabetic Wistar rats. J Submucosa Cytol Pathol. 2005;37:205–213.
5. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipO xygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006;30:45–51.
6. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF. Bone destruction by breast tumours. Prostaglandins. 1976;11:461–463.
7. Bennett A. Prostaglandins as factors in diseases of the alimentary tract. Adv Prostaglandin Thromboxane Res. 1976;2:547–555.
8. Claria J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des. 2005;11:3431–3447
9. Corazzi T, Leone M, Roberti R, Del Soldato P, Gresele P. Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. Biochem Biophys Res Commun. 2003;311:897–903.
10. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005;315:1331–1337.
11. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antago nists. Medicine (Baltimore). 2005;84:291–302.